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Abstract This literature review looks at the epidemiol-
ogy, clinical manifestations, diagnostics and current med-
ical and surgical management of Clostridium difficile
(C. difficile) infection. A literature search of PubMed and
Cochrane database regarding C. difficile infection was
performed. Information was extracted from 43 published
articles from 2000 to the present day which met inclusion
criteria. C. difficile is a gram-positive, anaerobic bacillus,
which is widely found in the environment, especially in the
soil. The occurrence of more resistant strains, which is
mainly connected with the wide use of antibiotics, resulted
in the rapid spread of the bacteria to different hospital
departments. Particularly, elderly patients in surgical wards
and intensive care units are at significant risk of developing
C. difficile infection, which greatly increases morbidity and
mortality. Symptoms of infection with C. difficile vary
greatly. At one end of the spectrum, there are asymptom-
atic carriers, at the other patients with life-threatening toxic
megacolon. Metronidazole is considered to be the drug of
choice, but recent guidelines recommend Vancomycin.
Fulminant colitis and toxic megacolon warrant surgical
intervention. The optimal time for surgery is within 48 h of
initiating conservative treatment without seeing a response,
the development of multiple organ failure or a bowel per-
foration. A factor that has become increasingly important
and relevant is the escalating expense of treatment for
patients with C. difficile infection. It is, therefore, highly
recommended to consider reviewing all hospital antibiotic
policies and clinical guidelines that may contribute to the
prevention of the infection.
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Introduction
The name ‘‘Clostridium difficile’’ (C. difficile) comes from
the Greek word ‘‘Kloster’’ which means spindle. It was first
mentioned in the literature in 1935 by Hall and O’Toole
[1]. At first, the bacterium was given the name ‘‘Bacillus
difficilis.’’ (Latin: difficilis, meaning difficult). This was
because of the difficulty encountered isolating the bacteria
and also the fact that it had a very slow growth phase
during culturing. The name was subsequently changed in
the 1970s to C. difficile.
Clostridium difficile is a gram-positive, anaerobic
bacillus, which is found widely in the environment, espe-
cially in the soil. Despite the fact that even in the first
known description of C. difficile the authors had mentioned
its deadly effects on mice, the complete virulence of the
bacterium was not properly recognized until much later.
During World War II, Hambre et al. [2] observed using
animal models that mice treated for gas gangrene with
penicillin suffered from a very severe form of typhlitis.
This in fact turned out to be even more deadly than the
gangrene itself caused by Clostridium perfringens. This
discovery led to new tests in which researchers gave
rodents different kinds of antibiotics watching for the
development of very similar symptoms. Green [3] used
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guinea pigs in his experiments, during which he was able to
induce death by giving them large doses of penicillin. He
then studied the stool of the dead guinea pigs and discov-
ered the presence of cytoplasmic changes within. This was
the first description of C. difficile toxin. It was Cohen and
colleagues [4] who actually documented the connection
between pseudomembranous colitis and antibiotic therapy.
One year after the publication of this association, Tadesco
et al. [5] had noticed that patients treated with clindamycin
(almost 21 %) suffered from diarrhea and (10 %) were
diagnosed with pseudomembranous colitis. This trial
involved over 200 patients and was the first trial in which
endoscopy was used so routinely on such a large group of
patients. It led to the identification of C. difficile as a
causative factor for multiple ailments involving the
digestive system.
Clostridium difficile is found in 66 % of the digestive
tracts of asymptomatic infants and young children. This
could be secondary to the fact that not all of the receptors
in the intestinal epithelium have matured completely. In
adults, colonization affects about 3 % of the population.
This number increases considerably during long hospital
stays and postoperatively. The bacteria are present mainly
in a vegetative form and are very sensitive to atmospheric
oxygen. Under the influence of considerable stress, they
may take the form of a spore and are thus able to survive
harsh environments, such as the acid content of the stom-
ach. With this resilience, C. difficile can find itself intact in
the small intestine and transform itself back into a vege-
tative form. It can then colonize the epithelial lining of the
mucosa in the digestive tract, and the problems caused by
the presence of bacteria are due to several different toxins
it produces. The best known are toxin A (enterotoxin) and
B (cytotoxin), which under favorable conditions are pro-
duced in copious amounts. Inside the cell membrane, these
toxins inactivate the transformation pathway mediated by
Rho family proteins, which are responsible for the proper
construction of actin cytoskeleton and the signal trans-
duction by GTP. This affects the cell and leads to cessation
from its regular cycle and apoptosis [6]. Both toxins also
affect the strength of the intercellular bonds [7]. The
relationship between the amount of toxins in the feces and
the severity of symptoms has been demonstrated. Signifi-
cant increases in toxins in the fecal load are associated with
the significant deterioration of the general condition of the
patient [8]. Toxin A leads to an increased secretion of fluid
within the digestive tract, mucosal inflammation and
structural damage. Toxin B is in most cases responsible for
the major problems associated with infection. It is esti-
mated that it has approximately 10 times more impact on
the gastrointestinal mucosa than toxin A [7]. Brito et al. [7]
came to the conclusion that the strains, which do not pro-
duce toxin A, are just as dangerous as those which have
both toxins. There is also a hypervirulent strain in exis-
tence, which was first observed at the beginning of the
twenty-first century. This particular strain is responsible for
the outbreaks of highly virulent pathogens and is referred
to as NAP1/BI/027. The complexity of the name is due to
the different methods applied in detecting the presence of
the bacteria: pulsed-field gel electrophoresis (NAP1),
restriction endonuclease analysis (BI) and polymerase
chain reaction (027). Type C toxin is produced by this
particular pathogen. The increasing frequency, with which
we now see treatment-resistant and more virulent strains of
the bacteria, led the authors of this paper to review the
literature on C. difficile infection and the treatment options
available.
Materials and methods
A literature was carried out using the electronic databases
of PUBMED and Cochrane (up to December 2012) for
relevant papers using the following terms: ‘‘Clostridium
difficile,’’ ‘‘Clostridium difficile infection,’’ ‘‘Clostridium
difficile treatment,’’ ‘‘Clostridium difficile colitis’’ and
‘‘Clostridium difficile fecal transplant,’’ limiting our search
to only English language articles. The reference lists of
used papers were also check and reviewed to identify
publications on the same topic.
Results
Information and data used for this publication were
obtained from 43 articles which met the searching criteria.
We excluded search results for which only an abstract
was available and case studies; however, we checked the
references from those we found to be interesting. We
included studies (review papers, meta-analysis and guide-
lines) which described the epidemiology and first publi-
cation about C. difficile infections. We compare different
papers and results according to the stage and conservative
treatment which was used. Data were collected from ori-
ginal papers referring to the possible surgical approaches,
those routinely and unusually used.
Data extraction regarding epidemiology, pathophysiol-
ogy, clinical manifestation with diagnosis and treatment of
the infection was completed by the first author and co-
reviewed by the second author.
Epidemiology
The occurrence of diarrhea and pseudomembranous colitis
significantly increased, immediately following the intro-
duction of widely available antibiotic treatments. At first,
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the use of clindamycin was connected with those ailments
and following this, the broad use of Penicillin. It took
many more years to identify C. difficile as being the
causative bacterium responsible for most of the symptoms
associated with the wide use of antibiotics. The simple
way in which the bacteria spread resulted in a significant
increase in the number of infections, especially among
hospitalized patients. The occurrence of more and more
resistant strains resulted in the rapid spread of the bacteria
to different departments, particularly the surgical wards
and intensive care units but also many other medical
wards. In a retrospective Canadian study, diarrhea and
pseudomembranous colitis were identified as occurring 4
times more frequently in the general population in 2003
than in 1991 and 10 times more frequently than in 1938
[9]. The same study noted a significant increase in the
symptoms of infection among hospitalized patients from 3
to 12 per 1,000 patients (the difference between 1991 and
2003) and up to 43 per 1,000 patients in 2004. Not only
has the number of cases grown significantly over the
years, but the severity has increased and the general
condition of the patient has deteriorated. More and more
patients, in addition to standard conservative treatment,
require surgery. In another study, 10 % of patients were
hospitalized in intensive care units and 2.5 % required an
emergency colectomy. The mortality in this study reached
16 % [10]. Similar statistics were observed in Europe and
the USA, where in 1999–2007, C. difficile was the main
contributor to death in patients with inflammatory bowel
disease [11].
Nosocomial infections are characterized by a much
more severe form of the disease than in the general pop-
ulation, and a higher incidence of C. difficile infection has
been noted, especially since 2000. This problem becomes
particularly apparent among the patients aged over
65 years. According to different authors, the frequency of
the carrier stage in patients with long hospital stays or those
treated in the intensive care units ranges from 20 to 50 %,
while in healthy adults, this quantity reaches only about
3 % [12]. Infected patients are often asymptomatic and
although they may not feel any discomfort, they act as a
reservoir for the bacteria and facilitate the spread of the
pathogen among other patients. Infection spreads easily by
the fecal–oral route and by direct contact with the patient
(fomites), in particular through the hands of hospital per-
sonnel, clothes and stethoscopes. Patients, who during their
hospital stay were already carriers, usually experience a
much milder form of infection or remain asymptomatic
[13]. The major risk factor for C. difficile infection is
widespread use of antibiotics, often without the appropriate
indications (Table 1). The use of antibiotics disrupts the
natural colonic flora, thereby providing C. difficile with the
opportunity to multiply and produce its toxins. Other risk
factors include long duration of admission, advanced age,
severe comorbidities, the use of proton pump inhibitors,
enteral feeding, gastrointestinal surgery, chemotherapy and
the use of tumor suppressor agents in postoperative trans-
plant patients [14].
Clinical presentations
Symptoms of infection with C. difficile are very diverse. At
one end of the spectrum, there are asymptomatic carriers at
the other patients with life-threatening toxic megacolon.
Infection and colonization itself are not the only pre-
requisite for the development of severe symptoms. What is
necessary is a major disturbance of the internal bacterial
flora, the risk factors which have already been mentioned
and the use of antibiotics, which all have an important role
in altering the intestinal flora.
Carrier stage
This spreads very quickly in the hospital environment, in
particular among patients treated in the intensive care units
and surgery departments. Most asymptomatic cases pro-
gress without any clinical manifestations. McFarland et al.
[15] studied 428 patients admitted to hospital within an
11-month period. Twenty-one percent of patients, who
were negative for C. difficile infection prior to hospital-
ization, were then subsequently indentified as asymptom-
atic carriers. Sixty-three percent remained carriers of the
infection until the end of the study. According to Lawrence
[16], as many as 50 % of hospitalized patients who have
had no prior contact with the pathogen become carriers
following lengthy hospital stays. Disruption of normal
intestinal flora can easily occur with the use of antibiotics
and the proliferation of bacteria within the gastrointestinal
tract, leaving the intestine susceptible to the adverse
influence of bacterial toxins. As previously mentioned, in
the carrier stage of C. difficile, the severity and frequency
of symptoms of the disease are limited. Research regarding
the treatment of carriers currently is scarce and is not
considered to be of benefit. Treatment of asymptomatic
carriers is not recommended [16].
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C. difficile-associated diarrhea (CDAD)
This bacterium is responsible for the majority of the cases
of diarrhea in hospitals. Its presence is significantly higher
in the hospital environment, where therapies that are used
require a different group of antibiotics, such as clindamy-
cin, cephalosporins, fluoroquinolones and penicillins [17].
Diarrhea usually occurs after 48–72 h after infection and is
often accompanied by severe abdominal pain and cramps.
There can be 10–15 bowel movements a day. A significant
number of stools per day can lead to changes in the elec-
trolyte and water balance. In patients with severe condi-
tions, especially after surgery, CDAD increases mortality
and morbidity rates.
C. difficile-associated colitis (CDAC)
Symptoms are very similar to those found in CDAD but
also include pyrexia and leukocytosis (with an average
white blood cell count of 15 9 109/L). Regarding the
physical examination, the most commonly elicited sign in
CDAC is abdominal guarding. Other findings can include
significant levels of dehydration and a positive fecal occult
blood test. A colonoscopy can be helpful at an early stage
as specific distinctive changes will be visible in the wall of
the bowel. These include characteristic erythematous
mucosa with noted friability and bleeding on contact
(Figs. 1, 2). Research from Wanahita et al. documents that
out of 60 patients with unexplained leukocytosis, 58 % had
stool cultures positive for the bacterial toxins. In such
cases, symptoms of diarrhea were observed approximately
24–48 h later [18]. Therefore, in cases of patients receiving
antibiotics who have a high white blood cell count (WBC),
even in the absence of diarrhea, C. difficile infection should
be suspected.
Pseudomembranous colitis
This is the most well-known form of C. difficile infection.
During endoscopy, a characteristic yellow plaque can be
observed in the mucosa of the colon and sometimes in the
terminal ileum, which forms the basis for early diagnosis
(Fig. 3). These plaques are small ulcerations of the mucous
membranes, which trigger the release of serum proteins, mucus
and inflammatory cells [6] (Fig. 4). Lymphocytes are found in
biopsies of the lesion(s), and the patient may be classified into
one of the three groups depending on the severity of infection
(Table 2). Accompanying symptoms include severe abdominal
pain, dehydration and often hypoalbuminemia (\30 mg/L). It
is essential to initiate the appropriate medical treatment for
patients with pseudomembranous colitis due to the potential
toxic effects of the infection.
Relapses occur in about 10–25 % of cured patients.
Frequently, re-infection can be much more severe, and
there is a greater predisposition to subsequent episodes of
pseudomembranous colitis [19].
Fulminant colitis
Generally, the natural progression of colitis allows one to
conceive and follow a treatment plan; however, sometimes
a fulminating form can develop. This form of inflamma-
tory bowel disease develops only in 3–8 % of the patients
[17]. A significant rise has been noted in recent years and
is associated with a hypervirulent strain of the bacteria.
This strain leads to the development of more systemic
Fig. 1 C. difficile colitis—picture 1 minor changes
Fig. 2 C. difficile colitis—picture 2 minor changes
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symptoms, multiple organ failure and overall increased
mortality. Findings during physical examination include
involuntary abdominal guarding. Full blood count analysis
tends to show a marked leukocytosis (40 9 109/L or more)
[18] and anemia secondary to bleeding from gastrointes-
tinal tract ulcers. Diarrhea can vary significantly,
depending on the course of the disease, from a few epi-
sodes per day to complete obstruction and dilatation of the
gastrointestinal tract. In the latter case, emergency surgical
intervention is required as the mortality rate in these
patients is very high and can reach 60 % [20], especially in
older patients. If an inpatient has no history of C. difficile
infection, diagnostic tests of the colon are still necessary.
Stool cultures should be obtained. Colonoscopy should be
performed by an experienced endoscopist in order to
minimize the volume of air blown into the colon. Due to
the risk of perforation, many doctors are wary of per-
forming a colonoscopy during an acute episode of colitis.
In fact, complications are quite rare (Fig. 5). The purpose
of performing an urgent colonoscopy is not to evaluate the
entire colon, but only to visualize the lining of the rectum
and the distal colon. If obvious features indicative of ful-
minant colitis are found during the procedure, the endos-
copist can simply remove the scope without having to
examine the entire bowel [21].
C. difficile-associated enteritis
Inflammation of the small intestine in the course of
C. difficile infection is quite rare. However, when it does
occur, it tends to be seen in patients postcolectomy and in
those with end ileostomies where high outputs are
observed. In elderly patients who have multiple comor-
bidities, treatment in special referral centers is advisable
[22].
Fig. 3 C. difficile pseudomembranous colitis
Fig. 4 C. difficile pseudomembranous colitis
Table 2 Histopathologic severity of pseudomembranous colitis
Classification Description of changes
Type 1 Mildest form, most of the changes are limited only to
the superficial epithelium. Pseudomembranous
changes are present, but ulcers are found only
occasionally
Type 2 More evident changes in the colonic mucosa, gland
disorders and significantly increased amount of
secreted mucus. Inflammation that invades the
basement membrane
Type 3 Full thickness necrosis is noticed within the whole
bowel wall with pseudomembranous changes
Fig. 5 Perforation in C. difficile colitis
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Appendicitis
Appendicitis in the course of C. difficile infection is very
rare. Up until 2007, only three cases have been described in
the literature. However, the authors suggest that this
complication may be significantly underdiagnosed, as
many of the cases may have responded well to the con-
servative treatment, and no histology samples/specimens
were available [23].
Diagnosis
Diagnostic evaluation of stool samples should be carried
out in patients with C. difficile infection who suffer from
clinically significant diarrhea, i.e., 3 or more episodes of
loose stool per day for 2 or more days. Other signs asso-
ciated with diarrhea such as pyrexia and leukocytosis are
suggestive of the diagnosis.
Laboratory tests
The easiest test is to detect the presence of toxins A and B
in the stool sample. An enzyme immunoassay (EIA) has
specificity up to 95 %, and the result is available after 4 h.
However, the sensitivity is significantly reduced to
70–80 % due to the large number of false negatives [24].
The most reliable test is a stool culture. The sensitivity of
this test reaches 90 %, but the results are not available for
approximately 4–5 days. In addition to this time delay, not
all laboratories routinely perform this assay. There are
some molecular techniques available to identify the pre-
sence of the genome and its replication. These include
polymerase chain reaction (PCR) ribotyping (a popular
method because of its availability, efficiency and high
specificity up to 97 % and sensitivity close to 91 %),
pulsed-field gel electrophoresis (PFGE), multilocus vari-
able number tandem repeat analysis (MLVA) and finally
multilocus sequence typing (MLST) [25].
Endoscopy
Colonoscopy and sigmoidoscopy are both valuable diag-
nostic tools in diagnosing C. difficile. In the case of pseu-
domembranous colitis, the visible findings typically
include a characteristic yellow plaque in the intestinal
mucosa with ulceration and some associated bleeding.
Table 3 shows the 4 main indications for colonoscopy
according to Hookman’a et al. [26]. In a patient with the
classical clinical symptoms and a positive stool culture, the
endoscopic examination may be waived. In the case of
fulminant colitis, it should, however, be performed, taking
special care not to cause perforation.
Imaging studies
A computed tomography (CT) scan of the abdomen and
pelvis may be helpful in the advanced stages, when the
wall of the intestine is characteristically thickened. Images
are not specific for bacterial infections [27].
Treatment
Clostridium difficile infection is one of the most common
causes of nosocomial infections and in particular is
responsible for increased morbidity and mortality in elderly
patients. The bacteria colonize the gastrointestinal tract,
when the physiological bacterial flora is disrupted due to
the use of antibiotics. Treatment of the infection depends
on the severity of the disease and the symptoms. It can be
treated conservatively or with surgery.
The most important initial treatment step is to cease
administration of the antibiotic that caused the C. difficile
infection (CDI). The continuous administrations of antibi-
otics, which do not treat C. difficile, not only worsen the
patient’s condition, but may also affect their susceptibility
to re-infection [28]. If, due to the primary disease, admin-
istration of antibiotics is required, it would be prudent to
incorporate antibiotics that are less responsible for extend-
ing CDI, such as aminoglycosides, sulfonamides, macro-
lides, tetracyclines and vancomycin. The general principles
of prevention of further infections should also be kept in
mind. Patients with suspected or confirmed CDI should be
placed in isolation because of the high risk of contamina-
tion. All medical staff should perform thorough hand
hygiene following contact with patients and also sanitize
any medical equipment used, e.g., stethoscope. Patients
should be well hydrated, and their electrolyte levels should
be carefully monitored. There are no dietary limitations
with the exception of patients who have surgery already
scheduled. In patients with typical symptoms of CDI, such
as diarrhea, abdominal pain, nausea and positive stool cul-
tures, antibiotics should be initiated [29]. Empirical therapy
is only indicated when there is a very high probability of
infection and while awaiting the results of diagnostic tests.
Carriers should not be treated with antibiotics when there
are no clinical symptoms of the infection.
Table 3 Indications for colonoscopy in the diagnosis of C. difficile
infection
Indications for diagnostic colonoscopy
1. The results of the laboratory tests are negative, but there is a
high probability of infection due to clinical symptoms
2. Earlier diagnosis required before the results of laboratory tests
3. Failure to respond to treatment with antibiotics
4. Atypical disease with obstruction and mild diarrhea
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In the treatment of less severe infections, initial therapy
should consist of metronidazole or vancomycin. Several
randomized clinical trials showed significant efficacy of
these antibiotics in the treatment of CDI [30]. Both drugs in
a study by Zar and colleagues [30] showed similar efficacy
(90–98 %), but metronidazole is considered to be the drug
of choice. The advantages of metronidazole are much
lower costs of the therapy and reduced spread of vanco-
mycin-resistant enterococci (VRE). Metronidazole should
be prescribed at a dose of 500 mg 3 times daily or 250 mg
4 times a day for 10–14 days. The oral dose of vancomycin
is 125 mg every 6 h. The use of higher doses such as
500 mg has no documented association with a shorter
recovery time. Intravenous forms of the medication are not
used as they have poor penetration into the gastrointestinal
tract [31]. Further examination of stool samples during
treatment is not indicative of response to treatment as
approximately 50 % of patients may have positive results
up to 6 weeks after cessation of treatment [31]. The use of
monoclonal antibodies against toxins A and B is a subject
of a great interest and hope. Currently they are not used or
recommended for routine treatment. Lowy et al. [32]
studied 200 patients to whom standard doses of antibiotics
were given (101 in the antibody group and 99 in the pla-
cebo group). The incidence of relapse was 7–25 %. More
randomized trials are needed to determine the benefit of
this therapy as a standard procedure.
Patients with severe infections may develop systemic
failure with copious diarrhea and must be treated in the
intensive care unit or surgical ward. There is no general
classification of ‘‘severity of infection’’ available, but in the
literature, a number of signs and symptoms are reported
that indicate which patients are candidates for intensive
therapy. These include white count C [15 9 109/L, ele-
vated creatinine, temperature [38.8 C and albumin
\2.5 mg/dL. Generally, the physicians clinical decision
and opinion are considered to be the most important when
initiating intensive treatments. Recent guidelines from
2010 [33] recommend vancomycin as the drug of choice.
Its main advantage is that vancomycin given orally is not
absorbed by the body so the full dose reaches the large
intestine, the site of infection. Many clinicians use Van-
comycin per os at a dose of 500 mg 4 times daily despite a
lack of evidence for the effectiveness of this therapy. The
recommended dose is still 125 mg 4 times daily [33]. In
patients refractory to this treatment, fidaxomicin or met-
ronidazole can be used. In patients with a bowel obstruc-
tion, vancomycin enemas with continuous oral [34] or
intravenous therapy, plus metronidazole every 8 h is
recommended.
Patients with severe and protracted infections can
sometimes develop rectal toxicity (toxicum megacolon),
perforation and necrosis of the intestine or rapidly
progressive infections with multiple organ failure. These
patients require surgical intervention [35]. The optimal
time for surgery is within 48 h of initiating conservative
treatment without seeing a response, the development of
multiple organ failure or a bowel perforation [20]. The
difficulty is in determining the optimal time for surgical
intervention as not all patients will survive the initial 48 h.
Considerations also need to be made regarding cases of
bowel obstruction and persistent diarrhea and vomiting
which are not suitable for conservative treatment. The
Canadian retrospective study already referred to [21]
showed that a colectomy was the most beneficial treat-
ment in patients above 65 years of age, with a WBC
[20 9 109/L and elevated serum lactate between 2.2 and
4.9 mmol/L. Positive peritoneal signs, obstruction, perfo-
ration and signs of toxic megacolon should also be
included in these criteria.
CDI infections are currently treated by two different
surgical approaches. One is subtotal colectomy. This
involves the removal of the entire colon with the creation
of an ileostomy, leaving the rectum in place. The other
procedure is less invasive—a diverting loop ileostomy with
colonic lavage.
Subtotal colectomy
The number of subtotal colectomies performed continues to
escalate due to the presence of hypervirulent strains of C.
difficile. Currently, about 5 % of patients infected with C.
difficile reach the stage of fulminant colitis and undergo
surgery. The procedure selected and the outcome depends
on the level of experience of the surgeon, but better results
are obtained in the case of total colectomy [36]. Earlier
surgical intervention is also associated with better results.
An emergency colectomy for advanced forms of C. difficile
is associated with higher mortality rates. Al-Abed et al. [37]
operated on 3.7 % of his patients with an associated mor-
tality rate of over 40 %. The majority of patients who had
significant comorbidities (75 %) did not survive after an
emergency colectomy. Anton D. Parera et al. [38] had very
similar results. The 30-day mortality rate was 45.7 %.
Therefore, it is crucial to identify infected patients early
before they progress into fulminant colitis and organ failure.
Diverting loop ileostomy with colonic lavage
This procedure may be an interesting alternative to a
colectomy. Neal et al. [39] operated on 42 patients using
this procedure. Comparing colectomy and diverting loop
ileostomy with lavage, the authors noted a reduction in
mortality from 50 to 19 %. After creating the ileostomy,
the colon may be flushed with warm polyethylene glycol.
Postoperatively vancomycin enemas can be administered
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123
via the ileostomy. This procedure was performed laparo-
scopically in 32 patients, which was equally effective and
less harmful to the patient at the same time. This is espe-
cially important among elderly patients.
Fecal transplant
As previously mentioned, a disruption in the balance of the
normal intestinal flora is a major risk factor for C. difficile
infection and indeed recurrent infections. In several
uncontrolled trials, the administration of stool from a
healthy donor has been used with a high degree of success
[40]. If a ‘‘fecal transplant’’ is considered, the donor should
be screened for transmissible diseases. Logistic issues to be
considered include timing, collection and processing of the
specimen from the donor. The feces can be delivered via
nasogastric tube or enema.
New treatments
Some new, interesting therapies are being tried and tested in
C. difficile treatment. Vancomycin therapy followed by rif-
aximin may be effective in the treatment of C. difficile
infection. In one series, 8 patients received a 2-week course
of rifaximin once they were clinically asymptomatic, after
the last administration of vancomycin. Seven patients had no
further recurrence of infection [41]. Also, intravenous
immunoglobulin (IVIG) containing C. difficile antitoxin has
been used in some patients with severe C. difficile colitis. A
retrospective review with a comparison to some case reports
revealed that there is no significant difference in the clinical
outcomes [42]. Probiotics may also be effective in the pre-
vention and treatment of CDAD, in several ways: the alter-
ation of intestinal flora, increased antimicrobial activity,
intestinal barrier protection and immunomodulation. The
clinical role of this therapy is an evolving area of study [43].
Discussion
In recent years, the number of nosocomial infections has
risen significantly. This is almost certainly because of the
overprescribing of antibiotics and one could certainly
question the clinical indications for said use. Also to blame
are the lengthy admission stays in surgical departments and
intensive care units. The demographics of the surgical
patient have changed in recent times, and there are now
more elderly and medically complex patients. Several
years ago, this subset of the population may have been
deemed unsuitable for surgical intervention and therefore
exempt from procedures. As we now routinely treat an
increasingly elderly subset of patients, we have to allow for
the fact that their average length of hospital stay is longer
than that of other patients. This group would realistically
stay more than 7 days as inpatients, thereby running a
major risk of contracting a C. difficile infection. In these
cases, preventative measures, a heightened level of
awareness and knowledge of early clinical symptoms are of
vital importance.
Obviously with the ever increasing severity of the
infection comes an associated increase in morbidity and
mortality. There are numbers of independent predictors of
mortality for CDAI (Table 4). Patients, who present with
these risk factors, especially with strong predictors, should
have early surgical consultations and early aggressive
surgical intervention should be considered.
The choice of initial treatment, surgical versus medical,
and the type of surgical resection influence the final out-
comes (Table 5).
If we take into account the lack of specific guidelines for
the treatment of C. difficile infection, and the number of
currently available surgical techniques, physicians and
surgeons have a considerable range of potential approaches
to use. Figure 6 shows the clinical approach to treatment of
C. difficile infection.
Table 4 Predictors of mortality for fulminant C. difficile colitis
Strong predictors of mortality for fulminant C. difficile colitis
1. Age C70 years
2. Severe infection WBC C35,000 or B4,000/lL or neutrophil
bands C10 %
3. Need for cardiorespiratory support (vasopressin or intubation)
4. Arterial lactate [4.9
5. Mental status change
Weak predictors of mortality for fulminant C. difficile colitis
1. Type of surgery (total colectomy vs. segmental resection)
2. Delayed surgical intervention
3. Admission to other than surgical ward
4. Multiple comorbidities
5. No vancomycin use during medical treatment
WBC white cell count
Table 5 Morbidity related to C. difficile infection and treatment
Morbidity after fulminant C. difficile colitis (%)
Overall 30-day mortality 34–57
5-Year survival rates 16.3–38
Subtotal colectomy and end ileostomy mortality rate 11
Segmental colectomy mortality rate 42–100
Diverting loop ileostomy with colonic lavage mortality rate 19
Stoma reversal rate 20
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Conclusions
Despite the overall positive results following a subtotal
colectomy, recent research shows that there is potential to
develop safer and less invasive techniques. The authors of
this study would like to highlight the ever increasing and
problematic issue of rising levels of nosocomial infections.
Further research is of paramount importance to help reduce
their occurrence.
Conflict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Hall C, O’Toole E (1935) Intestinal flora in newborn infants with
a description of a new pathogenic anaerobe, Bacillus difficilis.
Am J Dis Child 49:390–402
Fig. 6 Clinical approach to treatment of C. difficile infection
Tech Coloproctol (2014) 18:223–232 231
123
2. Hambre M, Rake G, McKee M et al (1943) The toxicity of pen-
icillin as prepared for clinical use. Am J Med Sci 206:642–652
3. Green RH (1974) The association of viral activation with peni-
cillin toxicity in guinea pigs and hamsters. Yale J Biol Med
47:166–181
4. Cohen E, McNeill J, Wells F (1973) Clindamycin-associated
colitis. J Am Med Ass 223:1379–1380
5. Tadesco J, Barton W, Alpers H (1974) Clindamycin-associated
colitis: a prospective study. Ann Intern Med 81:429–433
6. Riegler M, Sedivy R, Pothoulakis C et al (1995) Clostridium
difficile toxin B is more potent than toxin A in damaging human
colonic epithelium in vitro. J Clin Invest 95:2004–2011
7. Brito A, Sullivan W, Ciesla P et al (2002) Clostridium difficile
toxin A alters in vitro-adherent neutrophil morphology and
function. J Infect Dis 185:1297–1306
8. Akerlund T, Svenungsson B, Lagergren A et al (2006) Correla-
tion of disease severity with fecal toxin levels in patients with
Clostridium difficile-associated diarrhea and distribution of PCR
ribotypes and toxin yields in vitro of corresponding isolates.
J Clin Microbiol 44:353–358
9. Pepin J, Valiquette L, Alary E et al (2004) Clostridium difficile-
associated diarrhea in a region of Quebec from 1991 to 2003: a
changing pattern of disease severity. CMAJ 171:466–472
10. Pepin J, Valiquette L, Cossette B (2005) Mortality attributable to
nosocomial Clostridium difficile-associated disease during epidemic
caused by a hypervirulent strain in Quebec. CMAJ 173:1037–1042
11. Hall J, Curns T, McDonald C, Parashar UD, Lopman BA (2012)
The roles of Clostridium difficile and norovirus among gastro-
enteritis-associated deaths in the United States, 1999–2007. Clin
Infect Dis 55:216–223
12. Riggs M, Sethi K, Zabarsky F et al (2007) Asymptomatic carriers
are a potential source for transmission of epidemic and nonepi-
demic Clostridium difficile strains among long-term care facility
residents. Clin Infect Dis 45:992–998
13. Shim K, Johnson S, Samore H et al (1998) Primary symptomless
colonization by Clostridium difficile and decreased risk of sub-
sequent diarrhea. Lancet 351:663–666
14. Loo G, Bourgault M, Poirier L et al (2011) Host and pathogen
factors for Clostridium difficile infection and colonization. N Eng
J Med 365:1693–1703
15. McFarland V, Mulligan E, Kwok Y et al (1989) Nosocomial
acquisition of Clostridium difficile infection. N Engl J Med
26:204–210
16. Lawrence J (2007) Contemporary management of Clostridium dif-
ficile-associated disease. Gastroenterol Endosc News Speed 5:35–40
17. Adams D, Mercer W (2007) Fulminant Clostridium difficile
colitis. Curr Opin Crit Care 13:450–455
18. Wanahita A, Goldsmith A, Marino J et al (2003) Clostridium
difficile infection in patients with unexplained leukocytosis. Am J
Med 115:543–546
19. Fekety R, McFarland V, Surawicz M et al (1997) Recurrent
Clostridium difficile diarrhea: characteristics of and risk factors
for patients enrolled in a prospective, randomized, double-blinded
trial. Clin Infect Dis 24:324–333
20. Dallal M, Harbrecht G, Bojoukas J et al (2001) Fulminant
Clostridium difficile: an underappreciated and increasing cause of
death and complications. Ann Surg 235:363–372
21. Lamontagne F, Labbe´ AC, Haeck O et al (2007) Impact of
emergency colectomy on survival of patients with fulminant
Clostridium difficile colitis during an epidemic caused by a
hypervirulent strain. Ann Surg 245:267–272
22. Vesoulis Z, Williams G, Matthews B (2000) Pseudomembranous
enteritis after proctocolectomy: report of a case. Dis Colon
Rectum 43:551–554
23. Brown A, Rajappannair L, Dalton B et al (2007) Acute appen-
dicitis in the setting of Clostridium difficile colitis: case report
and review of the literature. Clin Gastroenterol Hepatol
9:969–971
24. Turgeon K, Novicki J, Quick J et al (2003) Six rapid tests for
direct detection of Clostridium difficile and its toxin in fecal
samples compared with the fibroblast cytotoxicity assay. J Clin
Microbiol 41:667–670
25. Kachrimanidou M, Malisiovas N (2011) Clostridium difficile
infection: a comprehensive review. Crit Rev Microbiol 37:178–187
26. Hookman P, Barkin S (2009) Clostridium difficile associated
infection, diarrhea and colitis. World J Gastroenterol 15:1554–1580
27. Bartlett G (2002) Clinical practice. Antibiotic-associated diar-
rhea. N Engl J Med 346:334–349
28. Hu Y, Katchar K, Kyne L et al (2009) Prospective derivation and
validation of a clinical prediction rule for recurrent Clostridium
difficile infection. Gastroenterology 136:1206–1214
29. Drekonja M, Butler M, MacDonald R et al (2011) Comparative
effectiveness of Clostridium difficile treatments: a systematic
review. Ann Intern Med 155:839–847
30. Zar A, Bakkanagari R, Moorthi M et al (2007) A comparison of
vancomycin and metronidazole for treatment of Clostridium
difficile-associated diarrhea, stratified by disease severity. Clin
Infect Dis 45:302–307
31. Fekety R, Silva J, Kauffman C et al (1989) Treatment of antibi-
otic-associated Clostridium difficile colitis with oral vancomycin:
comparison of two dosage regimens. Am J Med 86:15–19
32. Lowy I, Molrine DC, Leav BA et al (2010) Treatment with
monoclonal antibodies against Clostridium difficile toxins.
N Engl J Med 362:197–205
33. Cohen H, Gerding N, Johnson S et al (2012) Clinical practice
guidelines for Clostridium difficile infection in adults: 2010
update by the society for healthcare epidemiology of America
(SHEA) and the infectious diseases society of America (IDSA).
Infect Control Hosp Epidemiol 31:431–455
34. Apisarnthanarak A, Razavi B, Mundy M (2002) Adjunctive in-
tracolonic vancomycin for severe Clostridium difficile colitis: case
series and review of the literature. Clin Infect Dis 35:690–696
35. Sailhamer A, Carson K, Chang Y et al (2009) Fulminant Clos-
tridium difficile colitis: patterns of care and predictors of mor-
tality. Arch Surg 144:433–439
36. Butala P, Divino D (2010) Surgical aspects of fulminant Clos-
tridium difficile colitis. Am J Surg 200:131–135
37. Al-Abed Y, Gray E, Rothnie N (2010) Outcomes of emergency
colectomy for fulminant Clostridium difficile colitis. Surgeon
8:330–333
38. Perera A, Akbari R, Cowher M (2010) Colectomy for fulminant
Clostridium difficile colitis: predictors of mortality. Am Surg
76:418–421
39. Neal D, Alverdy C, Hall E et al (2011) Diverting loop ileostomy
and colonic lavage: an alternative to total abdominal colectomy
for the treatment of severe, complicated Clostridium difficile
associated disease. Ann Surg 254:423–427
40. Gustafsson A, Lund-Tonnesen S, Berstad A et al (1998) Faecal
short-chain fatty acids in patients with antibiotic-associated
diarrhea, before and after faecal enema treatment. Scand J Gas-
troenterol 33:721–727
41. Garey W, Ghantoji S, Shah N et al (2011) A randomized, dou-
bled-blind, placebo-controlled pilot study to assess the ability of
rifaximin to prevent recurrent diarrhea in patients with Clos-
tridium difficile infection. J Antimicrob Chemother 66:2850–
2855
42. Juand P, Skledar J, Zgheib K et al (2007) Clinical outcomes of
intravenous immune globulin in severe clostridium difficile-
associated diarrhea. Am J Infect Control 35:131–137
43. McFarland V (2006) Meta-analysis of probiotics for the preven-
tion of antibiotic associated diarrhea and the treatment of Clos-
tridium difficile disease. Am J Gastroenterol 101:812–822
232 Tech Coloproctol (2014) 18:223–232
123
